Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
Merck
Dow
McKesson

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR AURANOFIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Auranofin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00246064 ↗ The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol Completed Centocor Ortho Biotech Services, L.L.C. Phase 4 2001-12-01 The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering.
NCT01419691 ↗ Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed Kansas Bioscience Authority Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01419691 ↗ Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed The Leukemia and Lymphoma Society Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01419691 ↗ Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed Therapeutics for Rare and Neglected Diseases (TRND) Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01419691 ↗ Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed University of Kansas Medical Center Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01737502 ↗ Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2012-11-29 This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.
NCT01737502 ↗ Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting Mayo Clinic Phase 1/Phase 2 2012-11-29 This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Auranofin

Condition Name

Condition Name for Auranofin
Intervention Trials
HIV 2
Recurrent Fallopian Tube Cancer 1
Stage IV Non-Small Cell Lung Cancer 1
Chronic Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Auranofin
Intervention Trials
Dysentery, Amebic 2
Lung Neoplasms 2
Amebiasis 2
Carcinoma, Non-Small-Cell Lung 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Auranofin

Trials by Country

Trials by Country for Auranofin
Location Trials
United States 9
Brazil 1
Germany 1
Bangladesh 1
South Africa 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Auranofin
Location Trials
Minnesota 3
Florida 3
Kansas 2
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Auranofin

Clinical Trial Phase

Clinical Trial Phase for Auranofin
Clinical Trial Phase Trials
Phase 4 1
Phase 2 5
Phase 1/Phase 2 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Auranofin
Clinical Trial Phase Trials
Completed 7
Withdrawn 2
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Auranofin

Sponsor Name

Sponsor Name for Auranofin
Sponsor Trials
Mayo Clinic 5
National Cancer Institute (NCI) 4
National Institute of Allergy and Infectious Diseases (NIAID) 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Auranofin
Sponsor Trials
Other 16
NIH 7
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Express Scripts
McKinsey
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.